# Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).

Study · id `cardio:ct-nct03464019` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03464019](<https://clinicaltrials.gov/study/NCT03464019>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03464019

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1097 participants.

## Technical summary

Registry record NCT03464019. Randomized; quadruple masking; primary purpose treatment. Start 2018-06-18 (actual); primary completion 2023-01-20 (actual). Results posted on 2024-07-12.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1097 participants (enrolled count; ClinicalTrials.gov record NCT03464019, source copy `cardio:ctgov-nct03464019-2024-07-12`, retrieved 2026-10-26)
- Started: 2018-06-18 (actual) (ClinicalTrials.gov record NCT03464019, source copy `cardio:ctgov-nct03464019-2024-07-12`, retrieved 2026-10-26)
- Primary completion: 2023-01-20 (actual) (ClinicalTrials.gov record NCT03464019, source copy `cardio:ctgov-nct03464019-2024-07-12`, retrieved 2026-10-26)
- Completion: 2023-01-20 (actual) (ClinicalTrials.gov record NCT03464019, source copy `cardio:ctgov-nct03464019-2024-07-12`, retrieved 2026-10-26)
- Results first posted: 2024-07-12 (ClinicalTrials.gov record NCT03464019, source copy `cardio:ctgov-nct03464019-2024-07-12`, retrieved 2026-10-26)
- Countries: United States; Belgium; Canada; France; Germany; Hungary; Netherlands; Poland; Spain (ClinicalTrials.gov record NCT03464019, source copy `cardio:ctgov-nct03464019-2024-07-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03464019-2024-07-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).
- Acronym: NODE-301
- Condition: Paroxysmal Supraventricular Tachycardia
- Intervention (Drug): Etripamil
- Intervention (Drug): Placebo
- Intervention (Drug): Etripamil Test Dose
- Lead sponsor: Milestone Pharmaceuticals Inc.
- Lead sponsor class: OTHER
- Collaborator: Medpace, Inc.
- Collaborator class: INDUSTRY
- Collaborator: IQVIA Biotech
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Ventricular tachycardia (`cardio:ventricular-tachycardia`)
- Registry lists this organization as the lead sponsor: Milestone Pharmaceuticals Inc. (`cardio:org-milestone-pharmaceuticals-inc`)
- Registry lists this organization as a collaborator: Medpace, Inc. (`cardio:org-medpace-inc`)
- Registry lists this organization as a collaborator: IQVIA Biotech (`cardio:org-iqvia-biotech`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial (`cardio:pubmed-37331368`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 5eede922d26613402ad6828098ff0bb4f7b7beb54580c6400984bc184187b34a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
